Skip to content

Excess Iron in people with Sickle Cell Disease: assessment of iron absorbed by the intestine

Iron Overload in people with Sickle Cell Disease: evaluation of the intestinal absorption of this nutrient

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-4b7v8pt
Enrollment
Unknown
Registered
2023-07-06
Start date
2019-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle cell anemia without crisis

Interventions

The general objective of the study was to test the hypothesis that there is a reduction in the intestinal absorption of iron in people with sickle cell anemia and iron overload since the serum concent
SP4.606.635.419.496.912.431

Sponsors

Universidade do Estado do Rio de Janeiro
Lead Sponsor
Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti
Collaborator

Eligibility

Age
3 Years to 59 Years

Inclusion criteria

Inclusion criteria: Children from 2 to 10 years old; adolescents aged 11 to 18 years; adults: from 19 to 59 years old, divided into three groups. In group 1, patients with sickle cell anemia with the SS genotype confirmed by HPLC and who are being followed up at the Hemorio hematology outpatient clinic, with a serum ferritin concentration equal to or greater than 1000 ng/mL; in group 2, patients with sickle cell anemia (SS genotype) confirmed by High Performance Liquid Chromatography (HPLC) and who are followed up at the Hemorio hematology outpatient clinic, with serum ferritin concentration below 1000 ng/mL; in group 3, healthy individuals who do not have sickle cell anemia proven by HPLC

Exclusion criteria

Exclusion criteria: Participants with sickle cell anemia who have been hospitalized and/or received transfusions in the last 15 days prior to the assessment; individuals in the group without sickle cell anemia who have sickle cell trait or other haemoglobinopathies, hematological diseases and/or who use medication for diabetes mellitus and hypo/hyperthyroidism and/or who have serum ferritin less than 10 ng/mL for women and less than 20 ng/mL for men. Pregnant women were also excluded from both groups.

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: It is expected that there will be a reduction in intestinal iron absorption in people with sickle cell anemia and iron overload, and the rate of iron absorption will be assessed using the stable isotope labeling technique (57Fe).

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactMarta dos Reis

Universidade do Estado do Rio de Janeiro

martacitelli@gmail.com55 21 999302721

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 8, 2026